David Westenberg
Stock Analyst at Piper Sandler
(3.60)
# 749
Out of 4,829 analysts
172
Total ratings
45%
Success rate
6.32%
Average return
Main Sectors:
Stocks Rated by David Westenberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZTS Zoetis | Maintains: Overweight | $205 → $210 | $162.36 | +29.34% | 14 | May 12, 2025 | |
| LH Labcorp Holdings | Maintains: Neutral | $260 → $280 | $249.60 | +12.18% | 4 | May 6, 2025 | |
| NEO NeoGenomics | Maintains: Overweight | $18 → $12 | $8.39 | +43.03% | 9 | May 6, 2025 | |
| GH Guardant Health | Maintains: Overweight | $50 → $60 | $41.36 | +45.07% | 9 | May 6, 2025 | |
| FLGT Fulgent Genetics | Maintains: Neutral | $16 → $23 | $19.82 | +16.04% | 8 | May 6, 2025 | |
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $11 → $13 | $9.59 | +35.56% | 13 | May 6, 2025 | |
| DGX Quest Diagnostics | Maintains: Neutral | $180 → $200 | $174.87 | +14.37% | 7 | Apr 28, 2025 | |
| NEOG Neogen | Maintains: Neutral | $6.4 → $5 | $6.49 | -22.96% | 12 | Apr 22, 2025 | |
| AKYA Akoya Biosciences | Maintains: Neutral | $2.4 → $1.65 | $1.23 | +34.15% | 8 | Apr 14, 2025 | |
| ELAN Elanco Animal Health | Maintains: Neutral | $16 → $12 | $12.87 | -6.72% | 9 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $55 | $63.61 | -13.54% | 3 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $205 | $155.00 | +32.26% | 14 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8.5 → $8 | $3.07 | +160.59% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $70 | $53.55 | +30.72% | 10 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $2.5 → $2 | $1.16 | +73.16% | 7 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $185 → $190 | $80.98 | +134.63% | 15 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $435 → $510 | $507.99 | +0.40% | 10 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $3 | $2.80 | +7.14% | 7 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $9.47 | - | 1 | Mar 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $37.90 | - | 2 | Jan 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $44.87 | - | 1 | Nov 21, 2017 |
Zoetis
May 12, 2025
Maintains: Overweight
Price Target: $205 → $210
Current: $162.36
Upside: +29.34%
Labcorp Holdings
May 6, 2025
Maintains: Neutral
Price Target: $260 → $280
Current: $249.60
Upside: +12.18%
NeoGenomics
May 6, 2025
Maintains: Overweight
Price Target: $18 → $12
Current: $8.39
Upside: +43.03%
Guardant Health
May 6, 2025
Maintains: Overweight
Price Target: $50 → $60
Current: $41.36
Upside: +45.07%
Fulgent Genetics
May 6, 2025
Maintains: Neutral
Price Target: $16 → $23
Current: $19.82
Upside: +16.04%
Adaptive Biotechnologies
May 6, 2025
Maintains: Overweight
Price Target: $11 → $13
Current: $9.59
Upside: +35.56%
Quest Diagnostics
Apr 28, 2025
Maintains: Neutral
Price Target: $180 → $200
Current: $174.87
Upside: +14.37%
Neogen
Apr 22, 2025
Maintains: Neutral
Price Target: $6.4 → $5
Current: $6.49
Upside: -22.96%
Akoya Biosciences
Apr 14, 2025
Maintains: Neutral
Price Target: $2.4 → $1.65
Current: $1.23
Upside: +34.15%
Elanco Animal Health
Mar 6, 2025
Maintains: Neutral
Price Target: $16 → $12
Current: $12.87
Upside: -6.72%
Mar 4, 2025
Maintains: Neutral
Price Target: $70 → $55
Current: $63.61
Upside: -13.54%
Mar 4, 2025
Maintains: Overweight
Price Target: $200 → $205
Current: $155.00
Upside: +32.26%
Mar 4, 2025
Maintains: Overweight
Price Target: $8.5 → $8
Current: $3.07
Upside: +160.59%
Feb 26, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $53.55
Upside: +30.72%
Feb 20, 2025
Reiterates: Neutral
Price Target: $2.5 → $2
Current: $1.16
Upside: +73.16%
Feb 10, 2025
Maintains: Overweight
Price Target: $185 → $190
Current: $80.98
Upside: +134.63%
Feb 10, 2025
Maintains: Neutral
Price Target: $435 → $510
Current: $507.99
Upside: +0.40%
Nov 13, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $2.80
Upside: +7.14%
Mar 5, 2020
Initiates: Buy
Price Target: n/a
Current: $9.47
Upside: -
Jan 4, 2018
Upgrades: Buy
Price Target: n/a
Current: $37.90
Upside: -
Nov 21, 2017
Initiates: Neutral
Price Target: n/a
Current: $44.87
Upside: -